ChemicalBook > CAS DataBase List > Atorvastatin

Atorvastatin

Product Name
Atorvastatin
CAS No.
110862-48-1
Chemical Name
Atorvastatin
Synonyms
Atorvastatin;(rel)-Atorvastatin;Atorvastatin isomer;Atorvastatin, ?>98.0%;Atorvastatin(Relative);Atorvastatin Impurity 153;1H-PYRROLE-1-HEPTANOIC ACID;7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid;calcium 7-[4-[anilino(oxo)methyl]-2-(4-fluorophenyl)-3-phenyl-5-propan-2-yl-1-pyrrolyl]-3,5-dihydroxyheptanoate;(3S,5S)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
CBNumber
CB81269853
Molecular Formula
C33H35FN2O5
Formula Weight
558.64
MOL File
110862-48-1.mol
More
Less

Atorvastatin Property

Boiling point:
722.2±60.0 °C(Predicted)
Density 
1.23±0.1 g/cm3(Predicted)
pka
4.29±0.10(Predicted)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Atorvastatin Chemical Properties,Usage,Production

Definition

ChEBI: Atorvastatin is a dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases. It has a role as an environmental contaminant and a xenobiotic. It is an aromatic amide, a member of monofluorobenzenes, a statin (synthetic), a dihydroxy monocarboxylic acid and a member of pyrroles. It is functionally related to a heptanoic acid. It is a conjugate acid of an atorvastatin(1-).

Clinical Use

Hyperlipidaemia and hypercholesterolaemia

Drug interactions

Potentially hazardous interactions with other drugs Anti-arrhythmics: concentration possibly increased by dronedarone. Antibacterials: azithromycin, erythromycin, clarithromycin or fusidic acid possibly increased risk of myopathy - avoid atorvastatin for at least 7 days after fusidic acid stopped; concentration increased by clarithromycin - do not exceed 20 mg of atorvastatin1 ; avoid with telithromycin; increased risk of myopathy with daptomycin; concentration possibly reduced by rifampicin.
Anticoagulants: may transiently reduce anticoagulant effect of warfarin.
Antifungals: increased risk of myopathy with itraconazole - do not exceed 40 mg of atorvastatin1 ;
increased risk of myopathy with fluconazole, ketoconazole, posaconazole, voriconazole and possibly other imidazoles and triazoles - avoid.
Antivirals: increased risk of myopathy with atazanavir, boceprevir (reduce atorvastatin dose), and possibly darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir or tipranavir (max dose of atorvastatin 10 mg); concentration reduced by efavirenz and possibly etravirine; avoid with dasabuvir, ombitasvir, paritaprevir and telaprevir; possible increased risk of myopathy with ledipasvir - reduce atorvastatin dose; concentration increased by simeprevir - consider reducing atorvastatin dose.
Calcium channel blockers: concentration increased by diltiazem - increased risk of myopathy; concentration of verapamil increased also possible increased risk of myopathy - consider reducing atorvastatin dose.
Ciclosporin: increased risk of myopathy - do not exceed 10 mg of atorvastatin.1 Cobicistat: reduce atorvastatin dose.
Colchicine: possible increased risk of myopathy.
Grapefruit juice: concentration possibly increased.
Lipid lowering agents: increased risk of myopathy
with fibrates, gemfibrozil (avoid) and nicotinic acid.

Metabolism

Atorvastatin undergoes extensive presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Atorvastatin is metabolised by cytochrome P450 3A4 to ortho- and parahydroxylated derivatives and various beta-oxidation products. These products are further metabolised via glucuronidation. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. Atorvastatin is eliminated primarily in bile as active metabolites following hepatic and/or extrahepatic metabolism, but does not appear to undergo significant enterohepatic recirculation.

Atorvastatin Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Atorvastatin Suppliers

Triveni chemicals
Tel
--
Fax
--
Email
sales@trivenichemical.com
Country
India
ProdList
6088
Advantage
58
Dayaram Pharma Chem
Tel
--
Fax
--
Country
India
ProdList
32
Advantage
58
Vijayasri Organics Limited
Tel
--
Fax
--
Country
India
ProdList
10
Advantage
58
Festiva Pharma
Tel
--
Fax
--
Country
India
ProdList
237
Advantage
58
A.J Chemicals
Tel
--
Fax
--
Email
sales@ajchem.in
Country
India
ProdList
6100
Advantage
58
SL Drugs and Pharmaceuticals Pvt. Ltd.
Tel
--
Fax
--
Email
enquiry@sldrugs.com
Country
India
ProdList
2683
Advantage
50
More
Less

View Lastest Price from Atorvastatin manufacturers

Sigma Audley
Product
Atorvastatin 110862-48-1
Price
US $35.00-25.00/kg
Min. Order
1kg
Purity
99.8%
Supply Ability
200tons/year
Release date
2024-03-12
Career Henan Chemical Co
Product
Atorvastatin 110862-48-1
Price
US $2.00/KG
Min. Order
1g
Purity
98%min
Supply Ability
ask
Release date
2020-01-08

110862-48-1, AtorvastatinRelated Search:


  • Atorvastatin, ?>98.0%
  • 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-rel-
  • 1H-PYRROLE-1-HEPTANOIC ACID
  • (3S,5S)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
  • Atorvastatin
  • Atorvastatin(Relative)
  • calcium 7-[4-[anilino(oxo)methyl]-2-(4-fluorophenyl)-3-phenyl-5-propan-2-yl-1-pyrrolyl]-3,5-dihydroxyheptanoate
  • Atorvastatin isomer
  • (rel)-Atorvastatin
  • Atorvastatin Impurity 153
  • 7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
  • 110862-48-1
  • Cardiovascular Agents